MedTrace Logo

CD70-targeted immunoPET Imaging of Kidney Cancer

NCT06680089 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-12-31

No results posted yet for this study

Summary

The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.

Conditions

  • Urologic Neoplasms
  • Urogenital Neoplasms
  • Kidney Neoplasms
  • Neoplasms

Interventions

DRUG

[18F]RCCB6

Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]RCCB6 injection.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Wei Zhai, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

  • Weijun Wei, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-27
Primary Completion
2026-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06680089 on ClinicalTrials.gov